Related Experiment Video

Updated: Mar 1, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling Pathway

Jianwei Dai1, Yuyin Lin1, Youfa Duan2

  • 1GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou 510000, China.

International Journal of Biological Sciences
|May 26, 2017
PubMed

Insights

Andrographolide (Andro) effectively inhibits tumor angiogenesis by suppressing vascular growth and endothelial cell function. This natural compound targets miR-21-5p and TIMP3, showing potential as an anti-angiogenic cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor growth relies on angiogenesis, the formation of new blood vessels.
  • Andrographolide (Andro) exhibits anti-tumor properties, but its direct impact on angiogenesis is unclear.
  • Clarifying Andro's anti-angiogenic effects is crucial for cancer treatment development.

Purpose of the Study:

  • To investigate the direct effect of Andrographolide (Andro) on angiogenesis.
  • To elucidate the molecular mechanisms underlying Andro's anti-angiogenic activity.

Main Methods:

  • Inhibition of vascular growth was assessed using chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models.
  • In vitro studies evaluated the impact of Andro on vascular endothelial cell proliferation, migration, and tube formation.
  • Molecular mechanisms involving miR-21-5p and TIMP3 were analyzed.

Main Results:

  • Andrographolide (Andro) significantly inhibited vascular growth in CAM and YSM models.
  • Tumor angiogenesis was suppressed by Andro treatment.
  • Andro reduced proliferation, migration, and tube formation of vascular endothelial cells in vitro.
  • The anti-angiogenic effect was linked to the inhibition of miR-21-5p expression and subsequent targeting of TIMP3.

Conclusions:

  • Andrographolide (Andro) directly inhibits angiogenesis through molecular pathways involving miR-21-5p and TIMP3.
  • Andro demonstrates potential as an effective anti-angiogenic therapeutic agent for cancer treatment.
Keywords:
AndrographolideTIMP3.angiogenesismiR-21-5p

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K